A Weston company known for such MS drugs as Avonex and Tysabri, Biogen Idec said it has received a positive opinion on Tecfidera from the Committee for Medicinal Products for Human Use, which is recommending that European Union regulators approve the drug as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis.
A decision on Tecfidera by the US Food and Drug Administration is expected shortly.
“We believe Tecfidera will raise expectations for what people living with MS can achieve with their therapy,” Biogen Idec chief executive George Scangos said in a statement.
Earlier this week, Biogen Idec announced that the US Patent Office had granted it broad protection for Tecfidera.
Avonex is typically injected once a week. Tysabi is generally taken by infusion once a month. And Tecfidera is envisioned as a capsule taken twice a day.
Biogen’s stock closed Friday at $178, up almost one percent.